Background: Gene fusions often represent critical therapeutic targets across cancer subtypes. Fusions within the ErbB family of receptor tyrosine kinases, including EGFR, ERBB2 (HER2) and ERBB4 (HER4), have been previously described and represent potentially actionable alterations. Here, we report the relative incidence and functional characterization of these rare genomic events.
Publications
Incidence of ERBB gene fusions (EGFR, ERBB2, ERBB4) across tumor types
– Caris Life Sciences
Download Publication